NEW YORK--(BUSINESS WIRE)--Nephros, Inc. (AMEX:NEP) today reported that the Company received conditional approval for its Investigational Device Exemption (IDE) application from the Food and Drug Administration (FDA) to begin a human clinical trial of the Company’s OLpûr™ H2H™ Hemodiafiltration Module and OLpûr™ MD 220 Hemodiafilter. Nephros has been granted this approval on the condition that, by March 5, 2007, it will submit a response to two informational questions from the FDA. The Company has already provided a partial response to these questions.
